EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, AUGUST 5, 2013
Media Advisory: To contact author Christopher I. Li., MD., Ph.D., call Kristen Woodward at 206-667-5095 or email firstname.lastname@example.org. To contact commentary author Patricia F. Coogan, Sc.D., call Gina DiGravio at 617-638-8480 or email Gina.Digravio@bmc.org.
CHICAGO – Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine, a JAMA Network publication.
Antihypertensive medications are the most commonly prescribed class of drugs in the United States and in 2010 totaled an estimated 678 million filled prescriptions, Christopher I. Li, M.D., Ph.D., of the Fred Hutchinson Cancer Research Center, Seattle, and colleagues write in the study background.
“Evidence regarding the relationship between different types of antihypertensives and breast cancer risk is sparse and inconsistent, and prior studies have lacked the capacity to assess impacts of long-term use,” the study notes.
The population-based study in the three-county Seattle-Puget Sound metropolitan area included women ages 55 to 74 years: 880 of the women had invasive ductal breast cancer, 1,027 had invasive lobular breast cancer and 856 of them had no cancer and served as the control group. Researchers measured the risk of breast cancer and examined the recency and duration of use of antihypertensive medications.
According to the results, current use of calcium-channel blockers for 10 or more years was associated with higher risks of ductal breast cancer (odds ratio [OR], 2.4) and lobular breast cancer (OR, 2.6). The relationship did not vary much based on the type of calcium-channel blockers used (short-acting vs. long-acting or dihydropyridines vs. non-dihydropyridines). Other antihypertensive medications – diuretics, β-blockers and angiotensin II antagonists – were not associated with increased breast cancer risk, the results indicate.
“While some studies have suggested a positive association between calcium-channel blocker use and breast cancer risk, this is the first study to observe that long-term current use of calcium-channel blockers in particular are associated with breast cancer risk. Additional research is needed to confirm this finding and to evaluate potential underlying biological mechanisms,” the study concludes.
(JAMA Intern Med. Published online August 5, 2013. doi:10.1001/jamainternmed.2013.9071. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: This study was funded by the National Cancer Institute and the U.S. Department of Defense. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Calcium-Channel Blockers and Breast Cancer
In a related commentary, Patricia F. Coogan, Sc.D., of the Slone Epidemiology Center at Boston University, writes: “Given these results, should the use of CCBs [calcium-channel blockers] be discontinued once a patient has taken them for 9.9 years? The answer is no, because these data are from an observational study, which cannot prove causality and by itself cannot make a case for change in clinical practice.”
“Should the results be dismissed as random noise emanating from an observational study? The answer is no, because the data make a convincing case that the hypothesis that long-term CCB use increases the risk of breast cancer is worthy of being pursued,” Coogan continues.
“In conclusion, the present study provides valid evidence supporting the hypothesis that long-term CCB use increases the risk of breast cancer. If true, the hypothesis has significant clinical and public health implications,” Coogan concludes.
(JAMA Intern Med. Published online August 5, 2013. doi:10.1001/jamainternmed.2013.9069. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding andsupport, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.